Abstract: An integrated magnetic element includes an accommodating part; a current sensor disposed on the accommodating part; and a transformer disposed on the accommodating part. The transformer includes a magnetic core, a first winding including a plurality of wires, and a second winding, wherein some of the plurality of wires passes through the current sensor to shunt and detect current flowing through the first winding, and current values of the wires are detected by the current sensor to obtain a total current value of the first winding of the transformer according to a shunt ratio by the winding construction of the preset transformer.

Abstract: A current detection circuit and method for protecting a speaker, and a chip are provided. The current detection circuit includes a current detection module and an analog-to-digital converter. The current detection module samples a current flowing through the speaker based on current mirror technology, and converts the current into a voltage to output a first voltage signal and a second voltage signal. The analog-to-digital converter converts the first voltage signal and the second voltage signal into a PDM code, to calculate a current parameter of the speaker.

Abstract: The present application relates to the field of lifting equipment, in particular to a crane and a control method thereof.

Abstract: A method and device for controlling a DCDC converter, used for a hybrid electric vehicle and relating to the technical field of vehicle control. The method comprises: according to an output end current limit value and an actual voltage value, acquiring a first preset value corresponding to an input end power; according to the maximum discharge power of a high-voltage battery and the actual discharge power of an electric motor, acquiring a second preset value corresponding to the input end power; and determining the minimum value in the first preset value and the second preset value as an input end target power limit value. Multiple combination working conditions of sufficient or insufficient power sources at the input end are considered.

Abstract: The present disclosure discloses a contact angle measuring device, including a light source, a container, a photodetector, a bubble generating unit, and a processing unit. The container includes a first and a second side walls that are opposite. The first side wall is made of a light-transmitting material, the container is filled with a liquid with light transmission inside. The monochromatic light emitted by the light source passes through the first side wall and enters an interface between the first side wall and the liquid. The bubble generating unit is configured for generating a bubble that is in contact with an inner surface of the first side wall. The photodetector is configured for detecting light intensity distribution of the monochromatic light through the liquid.

Abstract: The present application provides a splicing display unit and a display screen, in order to visually eliminate the seam, improve the user's visual effect on splicing screens, and achieve a subjective visual feeling for the user as if there was no seam. The display screen includes a plurality of display modules and a plurality of optical structures, the plurality of display modules and the plurality of optical structures being closely arranged; each of the display modules includes a display area and a black edge area arranged around the display area, black edge areas of adjacent two display modules are spliced together to form a seam; one end of the first surface of the optical structure close to the seam is a first arc surface, and the first arc surface is configured to refract light emitted from the display area of the display module, and then distribute the refracted light in a front-view area corresponding to the seam.

Abstract: The embodiments of the present disclosure provide a display module and a middle frame, the display module includes a backlight module and a display panel, the backlight module includes a back plate, a first light source, a middle frame. The back plate includes a bottom plate, the first light source is on the bottom plate, the middle frame is between the bottom plate and the display panel. A side of the middle frame close to the display panel includes a first bearing portion and a second bearing portion, the first bearing portion is at an edge of the middle frame, a second light source is on the first bearing portion, the second bearing portion is on a side of the first bearing portion close to a display region of the display panel, the second bearing portion is connected to a position of the display panel corresponding to the display region.

Abstract: The application relates to specific binding members which bind the human epidermal growth factor receptor (EGFR). The specific binding members preferably comprise an EGFR antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members are expected to find application in the treatment of cancers expressing EGFR.

Abstract: The application relates to specific binding members which bind the human epidermal growth factor receptor (EGFR). The specific binding members preferably comprise an EGFR antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members are expected to find application in the treatment of cancers expressing EGFR.

Abstract: The application relates to antibody molecules, which bind to a first and second antigen, the first antigen being a disease antigen, for example a tumour antigen, and the second antigen being a tumour necrosis factor receptor superfamily (TNFRSF) receptor antigen on the surface of an immune cell. The antibody molecules preferably comprise a CDR-based antigen-binding site and an antigen-binding site, which may be located in two or more structural loops of a constant domain of the antibody molecule. The antibody molecules find application, for example, in cancer therapy.

Abstract: The application relates to specific binding members which bind the human epidermal growth factor receptor (EGFR). The specific binding members preferably comprise an EGFR antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members are expected to find application in the treatment of cancers expressing EGFR.

Abstract: The invention relates the use of Human Epidermal Growth Factor Receptor 2 (HER2) gene copy number and HER2 mRNA levels as biomarkers to identify cancers which will respond to treatment with a specific binding member comprising a HER2 antigen binding site engineered into a structural loop region of a constant domain, e.g. CH3 domain, of the specific binding member, and specific binding members which compete with such a binding member for binding to HER2.

Abstract: The present invention relates to an isolated antibody or fragment thereof, which specifically binds to human FGFR-3(IIIb) and FGFR-3(IIIc), or mutant forms thereof. Further embodiments include pharmaceutical compositions comprising the antibody and methods of using the antibody to treat cancer.

Abstract: The present invention is directed to an antibody or fragments thereof that are specific for a fibroblast growth factor receptor (FGFR)-1(IIIb), FGFR-1(IIIc), and/or FGFR-4. Also, provided herein, are vectors and host cells comprising the nucleic acids encoding those antibodies. The present invention further provides methods of antagonizing FGFR-1 or FGFR-4 as a treatment for obesity, diabetes, or a condition related thereto, and methods of reducing food intake.

Abstract: The present invention relates to an isolated antibody or fragment thereof, which specifically binds to human FGFR-3(IIIb) and FGFR-3(IIIc), or mutant forms thereof. Further embodiments include pharmaceutical compositions comprising the antibody and methods of using the antibody to treat cancer.

Abstract: The present invention relates to an isolated antibody or fragment thereof, which specifically binds to human FGFR-3(IIIb) and FGFR-3(IIIc), or mutant forms thereof. Further embodiments include pharmaceutical compositions comprising the antibody and methods of using the antibody to treat cancer.

Abstract: The present invention is directed to an antibody or fragments thereof that are specific for a fibroblast growth factor receptor (EGFR)-1(IIIb), EGFR-1(IIIc), and/or EGFR-4. Also, provided herein, are vectors and host cells comprising the nucleic acids encoding those antibodies. The present invention further provides methods of antagonizing EGFR-1 or EGFR-4 as a treatment for obesity, diabetes, or a condition related thereto, and methods of reducing food intake.

Abstract: The present invention relates to an isolated antibody or fragment thereof, which specifically binds to human FGFR-3(IIIb) and FGFR-3(IIIc), or mutant forms thereof. Further embodiments include pharmaceutical compositions comprising the antibody and methods of using the antibody to treat cancer.

Abstract: The present invention relates to an isolated antibody or fragment thereof, which specifically binds to human FGFR-3(IIIb) and FGFR-3(IIIc), or mutant forms thereof. Further embodiments include pharmaceutical compositions comprising the antibody and methods of using the antibody to treat cancer.

Abstract: The present invention relates to an isolated antibody or fragment thereof, which specifically binds to human FGFR-3(IIIb) and FGFR-3(IIIc), or mutant forms thereof Further embodiments include pharmaceutical compositions comprising the antibody and methods of using the antibody to treat cancer.